

Laboratory Solutions for Oncology Research

Scientific Expertise, Agility and Scale
for Optimized Solutions

The treatment of cancer remains one of the most prolific challenges of our generation. With new cancer cases predicted to rise to over 35 million globally by 2050, the demand for new and innovative treatment options has never been greater.¹

In the past decade, oncology research has focused on increasingly personalized treatments. These are designed to target cancerous cells, improving safety and survival rates, as well as quality of life for the patient.²

However, the rapid advancements in cancer treatment have come accompanied by new challenges, including stringent regulatory compliance and the need for specialized technologies.

Providing Solutions to the Challenges in Oncology Research

Selecting appropriate assay designs—our team of expert scientists is engaged from the start, leveraging their experience and knowledge to develop precise, fit-for-purpose assay designs.

Design, validation and delivery of assays to regulatory standards

We have the technology platforms, instruments and experts to execute a range of oncology testing including Flow Cytometry, Histopathology, Molecular Testing and Next Generation Sequencing.

Laboratory services for all phases

Laboratory services at every stage of the development process, from pre-clinical to phase IV, enables smooth transition between phases with continuity of assay availability and reducing the risk of delays.

Central laboratory set-up timelines that meet study requirements

Streamlined processes enable study set-up to be completed in as little as 6–8 weeks (depending on complexity).

Global deployment of assays

Assays are globally accessible, with our proven expertise in method/technology transfer and compliance with regional and local regulatory standards.



A Wide Range of Specialty Laboratory Solutions



Our biomarker services offer a range of solutions, including off-the-shelf panels, custom assay development, immunoassays, flow cytometry, molecular testing, next-generation sequencing, immunohistochemistry.

We provide comprehensive bioanalytical services across preclinical (GLP and non-GLP) and clinical phases, covering primary, secondary, and exploratory endpoints. We also offer full PK and immunogenicity programs for vaccines, biologics, and biosimilars.

Comprehensive Oncology/Immune-Oncology Specialty Testing Portfolio **Liquid and Solid Tumor**

Drug Prouct(s)				
Small molecules	Biologics/Biosimilars	Cell Therapy	Gene Therapy	Vaccines
(kinases, growth factors, DNA repair, platinum-based chemotherapies)	(monoclonal antibodies, bi-specifics, antibody-drug conjugates)	(CAR-T, CAR-NK, CAR-macrophage)	(adenovirus, oncolytic virus)	(prophylactic, therapeutic, peptide-based, personalized)
Bioanalytical Testing				
PK	Immunoassay	RT-PCR/ddPCR	RT-PCR/ddPCR (?)	RT-PCR/ddPCR (?)
Immunogenicity (humoral response)	Immunoassay	Immunoassay	Immunoassay	Immunoassay
Immunogenicity (humoral response)	–	ELISpot	ELISpot	ELISpot
Biomarker Testing				
Genomics	Molecular Biology	Histopathology	Flow Cytometry	Immunoassay
Assays				
TCR/BCR sequencing, RNA seq, single-gene, genome mapping, NGS, HLA typing, ctDNA panels (liquid biopsy), tumor mutational burden	NanoString, vector copy number, RCR/RCL, qPCR/ddPCR	IHC singleplex/multi-plex, spatial analysis, FISH/ISH	Immunophenotyping, intracellular cy-tokine staining, MRD (Euroflow), receptor occupancy	Cytokine profiling, specific tumor markers (soluble proteins)
Matrices				
Biological fluids	●	●	●	●
Bone marrow	●	●	●	●
Fine needle aspirate		●	●	
Tissue biopsy	●	●	●	●
Peripheral blood	●	●	●	●
Cell lines or culture or lysate	●	●	●	●

Global **Laboratory Network**

Cerba Research has a worldwide network of specialty laboratories delivering consistently high quality across a range of locations:

Flow Cytometry hubs located in New York, Ghent, Shanghai, Taipei and Sydney.

Histopathology and IHC Laboratory hubs in New York, Paris (Frepillon), Taipei, and Shanghai.

Genomics laboratories available in Paris, Rotterdam, Rijswijk, Taipei, Montreal, and New York.

Track Record of Experience and Success

Cerba Research is proud to have a vast portfolio of experience and expertise in providing cutting-edge medical research including

~170

oncology trials conducted since 2018.

~75

of trials include specialty testing.

26.8K

screened patients.

28

market authorizations/expansions.

x4

approved Cell and Gene Therapies (CGTs).

Approved indications include RRMM, mBC, neuroblastoma, NSCLC.

Cerba Research is a leading specialty laboratory services provider with the capacity and breadth of a global central laboratory network. Our highly qualified scientists provide insight on the latest biomarkers, assays and testing approaches and develop innovative solutions for unique challenges across all research phases, to pharmaceutical, biotechnology, medical device, government, public health, and CRO organizations.

Why Cerba Research?



Knowledgeable

Scientific expertise available for early engagement and consultation.



Agile

Flexible models according to protocol and study requirements.



Customizable

Laboratory solutions that meet your study goals to agreed timelines.



Turnaround time

Services at every phase delivered with speed and efficiency.

References

1. Global cancer burden growing, amidst mounting need for services [online] World Health Organisation, Available at: <https://www.who.int/news/item/01-02-2024-globalcancer-burden-growing--amidst-mounting-need-for-services> (Accessed on 21st February 2025)
2. A best practice guide for laboratory services in oncology trials [online] Cerba Research, Available at: https://www.cerbaresearch.com/wp-content/uploads/2024/12/CerbaResearch_Oncology_EBook_GridSystem_Master_V7-2-1.pdf (Accessed on 21st February 2025)

Interested in How We Can Shape Your **Laboratory Strategy** for Better Outcomes?

Get in touch today and see how Cerba Research
will support your next program.

cerbaresearch.com

